Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Overall survival · people with metastatic CRC

FOLFIRI + targeted therapy leads to lower overall survival compared with FOLFIRI (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.84 [0.77, 0.91]
6 studies · 3335 participants
High

Progression‐free survival · people with metastatic CRC

FOLFIRI + targeted therapy leads to lower progression‐free survival compared with FOLFIRI (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.78 [0.71, 0.87]
6 studies · 3335 participants
High

Tumour response · people with metastatic CRC

FOLFIRI + targeted therapy probably leads to higher overall tumour response compared with FOLFIRI (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.07 [1.31, 3.28]
6 studies · 3192 participants
Moderate

Severe adverse effects · people with metastatic CRC

FOLFIRI + targeted therapy probably leads to higher severe adverse effects compared with FOLFIRI (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.3 [1.17, 1.45]
6 studies · 3341 participants
Moderate